Joel Greenblatt's ALNY Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 39,622 shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $15.76 M, representing 0.06% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in ALNY, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 11,487 shares. Largest reduction occurred in Q1 2024, reducing 8,762 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Alnylam Pharmaceuticals (ALNY) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +11,487 | Add 40.83% | 39,622 | $397.65 |
| Q3 2025 | +10,348 | Add 58.18% | 28,135 | $456.00 |
| Q2 2025 | +3,270 | Add 22.53% | 17,787 | $326.09 |
| Q1 2025 | +3,593 | Add 32.89% | 14,517 | $270.02 |
| Q4 2024 | -6,651 | Reduce 37.84% | 10,924 | $235.31 |
| Q3 2024 | +4,338 | Add 32.77% | 17,575 | $275.03 |
| Q2 2024 | +11,190 | Add 546.65% | 13,237 | $243.00 |
| Q1 2024 | -8,762 | Reduce 81.06% | 2,047 | $149.45 |
| Q4 2023 | +7,727 | Add 250.71% | 10,809 | $191.41 |
| Q3 2023 | -775 | Reduce 20.09% | 3,082 | $177.10 |
| Q2 2023 | -1,259 | Reduce 24.61% | 3,857 | $189.94 |
| Q1 2023 | +1,730 | Add 51.09% | 5,116 | $200.32 |
| Q4 2022 | +3 | Add 0.09% | 3,386 | $237.65 |
| Q3 2022 | +277 | Add 8.92% | 3,383 | $200.12 |
| Q2 2022 | +1,808 | Add 139.29% | 3,106 | $145.85 |
| Q1 2022 | +1,298 | New Buy | 1,298 | $163.33 |
| Q2 2020 | -4,464 | Sold Out | 0 | $0.00 |
| Q1 2020 | +1,544 | Add 52.88% | 4,464 | $108.87 |
| Q4 2019 | +2,920 | New Buy | 2,920 | $115.07 |
| Q4 2017 | -2,499 | Sold Out | 0 | $0.00 |
| Q3 2017 | -7,185 | Reduce 74.19% | 2,499 | $117.65 |
| Q2 2017 | +9,684 | New Buy | 9,684 | $79.72 |
Joel Greenblatt's Alnylam Pharmaceuticals Investment FAQs
Joel Greenblatt first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q2 2017, acquiring 9,684 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Alnylam Pharmaceuticals, Inc. (ALNY) for 22 quarters since Q2 2017.
Joel Greenblatt's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q4 2025, adding 39,622 shares worth $15.76 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 39,622 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $15.76 M.
As of the Q4 2025 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.06% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 39,622 shares, as reported at the end of Q4 2025.